Neoantigen Cancer Vaccine Market 2026-2034 | Size, Trends & Opportunities

Coverage: Neoantigen Cancer Vaccine Market covers analysis By Product (Personalized neoantigen vaccines (patient-specific), Off-the-shelf neoantigen vaccines); Neoantigen Source/Type (Neoantigens derived from tumor mutations, Shared neoantigens/common tumor antigens); Vaccine Platform/Technology (Peptide?based, Nucleic acid (DNA/RNA) based., Dendritic cell/cell-based); Administration/Delivery Mode (Intravenous, Intramuscular, Other routes (e.g., intradermal)); End-Use Industry/Application (Hospitals & clinics, Specialized cancer treatment centers, Academic & research institutions); and Geography

  • Report Date : Feb 2026
  • Report Code : TIPRE00042202
  • Category : Life Sciences
  • Status : Upcoming
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 150

The global neoantigen cancer vaccine market is projected to grow from approximately US$ 495.05 million in 2025 to about US$ 1887.25 million by 2034, registering a CAGR of 16.03% during 2026‑2034.

Neoantigen Cancer Market Analysis

The neoantigen cancer vaccine market is being driven by several key factors, including the rising global burden of cancer and the shift toward personalized immunotherapies targeting tumor‑specific mutations. Technological enablers such as next‑generation sequencing, bioinformatics, and artificial intelligence for neoantigen prediction are accelerating the development of bespoke vaccines.

Furthermore, the ability to integrate neoantigen vaccines with immunotherapy regimens (e.g., checkpoint inhibitors) is broadening the therapeutic scope. Challenges remain, such as manufacturing complexity, regulatory pathways for individualized therapies, and demonstrating long‑term clinical benefit across diverse tumor types.

Neoantigen Cancer Market Overview

Neoantigen cancer vaccines are immunotherapies designed to elicit an immune response against tumor‑specific neoantigens, mutated proteins present only on cancer cells. These vaccines aim to stimulate T‑cells to recognize and eliminate malignant cells while sparing normal tissue.

In practice, the development workflow involves tumor biopsy, sequencing, neoantigen identification, vaccine manufacturing (e.g., mRNA, peptide, dendritic‑cell formats), and administration, often in combination with other immunotherapies. The market encompasses personalized (patient‑specific) and off‑the‑shelf neoantigen vaccines, with varied delivery platforms and end‑user settings.

Strategic InsightsNeoantigen Cancer Drivers and Opportunities

Market Drivers:

  • Rising incidence of cancer globally and demand for more effective, targeted immunotherapies.
  • Advances in sequencing, bioinformatics, and AI are enabling faster neoantigen discovery and vaccine development.
  • Growing partnerships between biotech/pharma and academia for neoantigen vaccine pipelines and combinations with checkpoint inhibitors.

Market Opportunities:

  • Expansion of off‑the‑shelf neoantigen vaccine platforms to improve scalability and cost‑effectiveness.
  • Emerging markets (such as Asia‑Pacific and other regions) with seeing oncology infrastructure and increasing adoption of precision medicine.
  • Integration of neoantigen vaccines with other modalities (e.g., cell therapies, checkpoint inhibitors) and leveraging AI/ML for enhanced epitope prediction and vaccine design.
Neoantigen Cancer Report Segmentation Analysis

The market is commonly segmented using the following taxonomy:

By Product:

  • Personalized neoantigen vaccines (patient‑specific)
  • Off‑the‑shelf neoantigen vaccines

By Neoantigen Source/Type:

  • Neoantigens derived from tumor mutations
  • Shared neoantigens / common tumor antigens

By Vaccine Platform / Technology:

  • Peptide‑based
  • Nucleic acid (DNA/RNA) ‑based.
  • Dendritic‑cell / cell‑based

By Administration / Delivery Mode:

  • Intravenous
  • Intramuscular
  • Other routes (e.g., intradermal)

By End‑Use Industry / Application:

  • Hospitals & clinics
  • Specialized cancer treatment centers
  • Academic & research institutions

By Geography:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Market Report Scope

Neoantigen Cancer Market Share Analysis by Geography
  • North America leads the market, driven by advanced oncology infrastructure, high adoption of personalized immunotherapies, and significant R&D investment.
  • Europe is a strong region with robust academic‑industry collaborations and favorable regulatory initiatives for personalized therapies.
  • Asia Pacific is one of the fastest‑growing markets, with rising healthcare expenditures, growing cancer burden, and increasing precision medicine adoption.

Emerging regions in Latin America, the Middle East & Africa present untapped opportunities, though currently smaller in share due to infrastructure and reimbursement challenges.

Neoantigen Cancer Market Players Density: Understanding Its Impact on Business Dynamics

The neoantigen cancer vaccine market features a mix of large biopharma and biotechnology companies, academic consortia, and niche players. This results in a densely competitive landscape with continuous innovation.

Key competitive strategies include:

  • Rapid neoantigen discovery and vaccine manufacturing turnaround
  • Leveraging AI and genomics for predictive accuracy
  • Collaborations/licensing with academic centers and major oncology players
  • Scaling personalized therapies into broader patient populations via off‑the‑shelf platforms
Major Companies operating in the Neoantigen Cancer Vaccine Market
  1. Moderna, Inc.
  2. BioNTech SE
  3. Merck & Co., Inc.
  4. F. Hoffmann‑La Roche Ltd
  5. Gritstone Bio, Inc.
  6. Agenus Inc.
  7. OSE Immunotherapeutics SA
  8. Advaxis, Inc.
  9. Medigene AG
  10. Genocea Biosciences, Inc.
Other companies analyzed during the course of research:
  1. Neon Therapeutics, Inc.
  2. Vaccibody AS
  3. BrightPath Biotherapeutics Co. Ltd
  4. Novogene Co. Ltd
  5. Immunovative Therapies Ltd.
  6. Frame Therapeutics GmbH
Neoantigen Cancer Market News and Recent Developments
  • The neoantigens market is projected to reach USD 10.55 billion by 2028 with a CAGR of 31.2%, highlighting the growing impact of AI in neoantigen vaccine development.
  • A new industry report indicates the global neoantigen cancer vaccine market grew from approximately USD 378.66 million in 2024 to USD 434.55 million in 2025, and is expected to reach USD 876.78 million by 2030 at a CAGR of ~15.0%.
  • Recent published research underscores the increased use of personalized neoantigen vaccine platforms, with updated trial data highlighting T‑cell responses in patients across tumor types.
Neoantigen Cancer Market Report Coverage and Deliverables

The report “Neoantigens Market Forecast to 2028 – COVID‑19 Impact and Global Analysis by Treatment and Therapeutic Specialty” from The Insight Partners provides:

  • Size and forecast of the neoantigen cancer vaccine market at the global, regional, and country levels for all key segments
  • Trends, drivers, restraints, and key opportunities in the market
  • Detailed PEST and SWOT analyses
  • Market analysis covering key market trends, global and regional frameworks, major players, key regulations, and recent developments
  • Industry landscape and competition analysis, including market concentration, heat map, prominent players, and recent developments
  • Detailed company profiles
REGIONAL FRAMEWORK
World Geography

Have a question?

Analyst

Mrinal

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst   Speak to Analyst
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities
MARKET PLAYERS
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which regions are leading in the adoption of neoantigen cancer vaccines?

1. North America: dominant region due to robust oncology infrastructure and R&D.
2. Europe: strong adoption supported by academic‑industry collaborations.
3. Asia Pacific: fastest‑growing region, driven by increasing precision medicine uptake and expanding biotech capacity.

Which industries are the primary end‑users of neoantigen cancer vaccines?

1. Hospitals & clinics (largest current usage for therapeutic administration)
2. Specialized cancer treatment centers and research institutions (growing segment)
3. Academic & research institutions focused on clinical trials and neoantigen development.

Which product component is gaining traction in the global neoantigen cancer vaccine market?

Personalized neoantigen vaccines are currently dominant; off‑the‑shelf platforms are gaining traction due to their potential for scalability and cost‑efficiency.

Which challenges hinder the neoantigen cancer vaccine market growth?

1. High development and manufacturing costs for personalized therapies.
2. Complexity and turnaround time for sequencing and vaccine design.
3. Limited long‑term clinical data and regulatory pathways for novel personalized vaccines

What are the key drivers of the neoantigen cancer vaccine market growth?

1. Rising cancer incidence and the need for more effective therapies.
2. Advances in sequencing, AI, and bioinformatics are enabling neoantigen discovery.
3. Collaborations between biotech/pharma and academia for personalized vaccines.

Your Key Concerns Addressed - Question & Answer
Can I view a sample of the report before purchasing?

Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.

Is analyst support included with the purchase?

Absolutely - analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.

What are the next steps once I place an order?

Once your order is successfully placed, you will receive a confirmation email along with your invoice.

• For published reports: You'll receive access to the report within 4-6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.

Can the report be tailored to suit my specific needs?

We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we'll be happy to provide a customized proposal or scope.

In what format is the report delivered?

The report is available in either PDF format or as an Excel dataset, depending on the license you choose.

The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.

How secure is the payment process on your platform?

Our payment process is fully secure and PCI-DSS compliant.

We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.

Do you provide special pricing for buying multiple reports?

Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we're happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you're considering, and we'll share a personalized quote.

Can I connect with your team to discuss the report before buying?

Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report's scope, methodology, customization options, or which license suits you best, we're here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.

Will I get a billing invoice upon purchase?

Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we'll be happy to assist.

Is there support available if I can't access my report?

Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we'll ensure the issue is resolved quickly so you can access your report without interruption.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.